Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRD known ✓ | O14764 | 2/20 | 0.50 |
| ▸ | GABRA1 known ✓ | P14867 | 2/20 | 0.50 |
| ▸ | GABRB1 known ✓ | P18505 | 2/20 | 0.50 |
| ▸ | GABRA5 known ✓ | P31644 | 2/20 | 0.50 |
| ▸ | GABRA3 known ✓ | P34903 | 2/20 | 0.50 |
| ▸ | GABRA2 known ✓ | P47869 | 2/20 | 0.50 |
| ▸ | GABRB2 known ✓ | P47870 | 2/20 | 0.50 |
| ▸ | GABRA4 known ✓ | P48169 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.53 |
| ▸ | USP2 | O75604 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL485154 | 0.98 | CYP1A2 (0.56) | CYP1A2CYP2D6GABRDGABRA1GABRB1 | |
| SCHEMBL484636 | 0.90 | CYP1A2 (0.54) | CYP1A2CYP2D6GABRDGABRA1GABRB1 | |
| SCHEMBL1725493 | 0.86 | L3MBTL3 (0.47) | CYP1A2CYP2D6GABRDGABRA1GABRB1 | |
| SCHEMBL484826 | 0.86 | CYP1A2 (0.49) | CYP1A2CYP2D6GABRDGABRA1GABRB1 | |
| SCHEMBL933548 | 0.82 | USP2 (0.41) | CYP1A2CYP2D6USP2ALDH1A1CYP2C19 | |
| Hydrochloric Acid SCHEMBL744621 | 0.82 | CYP1A2 (0.57) | CYP1A2CYP2D6GABRDGABRA1GABRB1 | |
| Hydrochloric Acid SCHEMBL2437534 | 0.81 | NAMPT (0.38) | CYP1A2CYP2D6GABRDGABRA1GABRB1 | |
| Hydrochloric Acid SCHEMBL2434750 | 0.81 | CYP1A2 (0.42) | CYP1A2CYP2D6GABRDGABRA1GABRB1 | |
| Hydrochloric Acid SCHEMBL8486057 | 0.80 | HSD11B1 (0.41) | CYP1A2CYP2D6USP2CYP2C19 | |
| SCHEMBL5431079 | 0.79 | CYP1A2 (0.54) | CYP1A2CYP2D6GABRDGABRA1GABRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260071223-A1 | LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS TO ADIPOSE TISSUE | ARROWHEAD PHARMACEUTICALS INC (US) | 2026-03-12 | — | — | US | disclosed |
| EP-4646213-A1 | LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS TO ADIPOSE TISSUE | Arrowhead Pharmaceuticals, Inc. (US) | 2025-11-12 | — | — | EP | disclosed |
| US-20250223597-A1 | LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS TO CNS TISSUE | ARROWHEAD PHARMACEUTICALS INC (US) | 2025-07-10 | — | — | US | disclosed |
| EP-4539886-A2 | LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS TO CNS TISSUE | Arrowhead Pharmaceuticals, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| EP-4540390-A2 | RNAI AGENTS FOR INHIBITING EXPRESSION OF SUPEROXIDE DISMUTASE 1 (SOD1), COMPOSITIONS THEREOF, AND METHODS OF USE | Arrowhead Pharmaceuticals, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| CN-119768186-A | Lipid conjugates for delivery of therapeutic agents to CNS tissues | 箭头药业股份有限公司 | 2025-04-04 | — | — | CN | disclosed |
| CN-119730859-A | RNAi agents for inhibiting superoxide dismutase 1 (SOD 1) expression, compositions and methods of use thereof | 箭头药业股份有限公司 | 2025-03-28 | — | — | CN | disclosed |
| WO-2024148329-A1 | LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS TO ADIPOSE TISSUE | Arrowhead Pharmaceuticals, Inc. (US) | 2024-07-11 | — | — | WO | disclosed |
| US-11912997-B2 | RNAi agents for inhibiting expression of Superoxide Dismutase 1 (SOD1), compositions thereof, and methods of use | Arrowhead Pharmaceuticals, Inc. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20240026363-A1 | RNAi Agents for Inhibiting Expression of Superoxide Dismutase 1 (SOD1), Compositions Thereof, and Methods of Use | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2024-01-25 | — | — | US | disclosed |
| US-20090215807-A1 | Novel Diazaspiroalkanes and Their Use for Treatment of CCR8 Mediated Diseases | ASTRAZENECA AB (SE) | 2009-08-27 | — | — | US | disclosed |
| US-20090118318-A1 | Novel Diazaspiroalkanes and Their Use for Treatment of CCR8 Mediated Diseases | ASTRAZENECA AB (SE) | 2009-05-07 | — | — | US | disclosed |
| EP-1926730-A1 | NOVEL DIAZASPIROALKANES AND THEIR USE FOR TREATMENT OF CCR8 MEDIATED DISEASES | AstraZeneca AB (SE) | 2008-06-04 | — | — | EP | disclosed |
| EP-1869045-A1 | NOVEL DIAZASPIROALKANES AND THEIR USE FOR TREATMENT OF CCR8 MEDIATED DISEASES | AstraZeneca AB (SE) | 2007-12-26 | — | — | EP | disclosed |
| EP-1869044-A1 | NOVEL DIAZASPIROALKANES AND THEIR USE FOR TREATMENT OF CCR8 MEDIATED DISEASES | AstraZeneca AB (SE) | 2007-12-26 | — | — | EP | disclosed |
| EP-1869046-A1 | NOVEL DIAZASPIROALKANES AND THEIR USE FOR TREATMENT OF CCR8 MEDIATED DISEASES | AstraZeneca AB (SE) | 2007-12-26 | — | — | EP | disclosed |
| WO-2007030061-A1 | NOVEL DIAZASPIROALKANES AND THEIR USE FOR TREATMENT OF CCR8 MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2007-03-15 | — | — | WO | disclosed |
| WO-2006107254-A1 | NOVEL DIAZASPIROALKANES AND THEIR USE FOR TREATMENT OF CCR8 MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2006-10-12 | — | — | WO | disclosed |
| WO-2006107253-A1 | NOVEL DIAZASPIROALKANES AND THEIR USE FOR TREATMENT OF CCR8 MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2006-10-12 | — | — | WO | disclosed |
| WO-2006107252-A1 | NOVEL DIAZASPIROALKANES AND THEIR USE FOR TREATMENT OF CCR8 MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2006-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11912997-B2 | RNAi agents for inhibiting expression of Superoxide Dismutase 1 (SOD1), compositions thereof, and methods of use | SOD1, SOD3, SMN1; SMN2 | GABRD 3038/4885GABRA1 3687/4885GABRB1 2670/4885 |
| US-20090118318-A1 | Novel Diazaspiroalkanes and Their Use for Treatment of CCR8 Mediated Diseases | CCR8, CCR1, CCR10 | GABRD 1402/4885GABRA1 591/4885GABRB1 550/4885 |
| US-20240026363-A1 | RNAi Agents for Inhibiting Expression of Superoxide Dismutase 1 (SOD1), Compositions Thereof, and Methods of Use | SOD1, SOD3, SMN1; SMN2 | GABRD 3019/4885GABRA1 3691/4885GABRB1 2623/4885 |
| US-20090215807-A1 | Novel Diazaspiroalkanes and Their Use for Treatment of CCR8 Mediated Diseases | CCR8, CCR1, CCRL2 | GABRD 1931/4885GABRA1 820/4885GABRB1 653/4885 |
| US-20260071223-A1 | LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS TO ADIPOSE TISSUE | FABP4, PLIN1, PLIN3 | GABRD 4724/4885GABRA1 4848/4885GABRB1 4744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.